Zydus US subsidiary acquires speciality drug asset in US

Zydus Lifesciences on Tuesday said its US subsidiary Sentynl Therapeutics entered in agreement to buy Nasdaq listed BridgeBio Pharma's speciality asset Nulibry (fosdenopterin) used in treatment of rare genetic disorder that affects children. Under the terms of the agreement, Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing Zydus Lifesciences on Tuesday said its US subsidiary Sentynl Therapeutics entered in agreement to buy Nasdaq listed BridgeBio Pharma's speciality asset Nulibry (fosdenopterin) used in treatment of rare genetic disorder that affects children. Zydus didn't specify the financial details of the deal. Sentynl will acquire global rights to Nulibry and will be responsible for the ongoing development and BridgeBio will share development responsibilities for fosdenopterin through approval of the marketing authorisation application already under accelerated assessment with the European Medicines Agency and through approval of its regulatory submission with the Israeli Ministry of Health. Sentynl will provide cash payments upon the achievement of certain regulatory milestones. BridgeBio will be eligible to receive commercial milestone payments as well as tiered royalties on adjusted net sales of Nulibry. Nulibry which is approved by USFDA is used for treatment of patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder that causes neurological damage. Zydus said Sentynl is also facilitating early diagnosis and treatment by enhancing awareness, new-born screening, genetic testing and patient support across multiple products and rare diseases including the development of a treatment for Menkes Disease, currently under rolling review by the USFDA, for which it partnered with Cyprium Therapeutics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!